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Abstract
Biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA) coating for applications in drug-eluting 
stents has been receiving increasing interest as a result of its unique properties compared with 
biodurable polymers in delivering drug for reducing stents-related side effects. In this work, a 
mathematical model for describing the PLGA degradation and erosion and coupled drug release 
from PLGA stent coating is developed and validated. An analytical expression is derived for 
PLGA mass loss that predicts multiple experimental studies in the literature. An analytical model 
for the change of the number-average degree of polymerization (or molecular weight) is also 
derived. The drug transport model incorporates simultaneous drug diffusion through both the 
polymer solid and the liquid-filled pores in the coating, where an effective drug diffusivity model 
is derived taking into account factors including polymer molecular weight change, stent coating 
porosity change, and drug partitioning between solid and aqueous phases. The model is used to 
describe in vitro sirolimus release from PLGA stent coating, and demonstrates the significance of 
simultaneous sirolimus release via diffusion through both polymer solid and pore space. The 
proposed model is compared to existing drug transport models, and the impact of model 
parameters, limitations and possible extensions of the model are also discussed.
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1. Introduction
Drug-eluting stents (DES) are predominantly used in coronary angioplasty procedures for 
reducing in-stent restenosis. Their distinguished therapeutic effect is attributed to the 
prolonged local release of anti-inflammatory or antiproliferative drugs from a polymeric 
stent coating into the arterial wall 1. Biodurable polymers are most commonly used for the 
stent coatings in DES, which release only part of the loaded drug and induce problems 
related to the intact polymer coating remaining in the arterial lumen after release (such as 
hypersensitivity reactions and late in-stent thrombosis) 2,3. The need of overcoming those 
problems has led to research on improving the DES techniques, and special attention has 
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been paid on the evaluation of biodegradable polymers, in particular poly(D,L-lactic-co-
glycolic acid) (PLGA), as alternative drug carriers 4,5.
PLGA has been well recognized for its suitability in drug delivery due to its good 
biocompatibility and ability to achieve complete drug release as a result of degradation and 
erosion of the polymer matrix 6,7. While degradation and erosion are intricately connected, 
they correspond to different processes. Degradation is a chemical process that involves 
scission of polymer backbones and formation of monomers and oligomers, and erosion is a 
physical phenomenon designating the loss of material resulted from the monomers and 
oligomers leaving the matrix 8. Polymer molecular weight (MW) change and mass loss are 
the two measures for quantifying degradation and erosion, respectively. Degradation and 
erosion are coupled to each other, and they collectively regulate the drug release rate in the 
PLGA stent coating 6. Experimental studies have been carried out for studying and 
designing PLGA stent coatings 9-12, which are based on the trial-and-error procedures. 
Complementarily, mathematical models could provide guidance in device design and 
optimization prior to or in concert with experimental procedures. While the literature is 
considerably rich in mathematical models for drug release from biodurable stent coatings (to 
name just a few, 13-16), there is limited work in modeling biodegradable stent coatings for 
drug delivery.
Modeling the PLGA degradation and erosion is a prerequisite for drug release modeling, and 
mechanistic approaches are most commonly employed, as described in papers on PLGA-
based drug delivery systems such as microspheres 17,18. A simple and convenient approach 
for describing degradation, or the molecular weight change, uses first-order degradation 
models 19-22. Some other models generate a system of equations for all polymer chain 
lengths and compute the whole molecular weight distribution 23,24. Such approaches have 
high computational costs and require very detailed information for model initialization. As 
an alternative, a moments model adopts a “shrinking core” approach to significantly reduce 
the number of equations 25. The moments model was extended by adding a monomer 
diffusion term for capturing the transition between reaction-controlled and diffusion-
controlled states 26. A limitation of the moments model is often the closure problem of 
second or higher order moments, which requires advanced treatment 27,28. PLGA erosion, or 
mass loss, is important but yet limited modeling works are available in the literature. Among 
those works, a combined bulk random scission and end scission model was proposed for 
explaining the measured molecular weight change and mass loss in PLGA microspheres 23. 
A threshold of dissolvable oligomer size has been assumed in the calculation of the 
measured polymer molecular weight and weight loss 24.
The autocatalytic effect, which occurs due to accumulation of acidic monomers and small 
oligomers in the interior of the PLGA matrix and results in a heterogeneous degradation 
rate, is also included by adding an acid concentration dependency on the rate constants 29. 
Assuming no mass loss and constant volume, a simple analytical expression for the number 
average molecular weight in autocatalytic hydrolysis has been derived 29. A mass balance 
model was also developed for three species (polymer PLA, oligomer, and monomer) where 
the monomer was considered to contribute to the autocatalytic effect 30. Existing treatments 
of autocatalytic effect are summarized in a recent review 31. Although interesting, the 
Zhu and Braatz Page 2
J Biomed Mater Res A. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
application of PLGA stent coating typically has a small characteristic length for which 
spatial non-uniformity of proton distribution disappears and the autocatalytic effect was not 
observed 10.
Accompanied and facilitated by PLGA degradation and erosion, drug release undertakes 
significant impact from the changing properties of the polymer matrix (porosity and PLGA 
molecular weight) and such factors need to be captured in the diffusion drug transport. For 
heparin release in PLGA microsphere, the pore size was modeled and an induction time for 
drug release was calculated 23. The model, however, used constant drug diffusivity for its 
drug release calculation. While macromolecular hydrophilic drugs are limited by diffusion 
through the pore space, relatively smaller hydrophobic drugs could diffuse through both the 
PLGA matrix and the pore space. Several models have considered an effective drug 
diffusivity dependent on polymer molecular weight change (summarized in Table 1) 6. The 
diffusivity was considered as being inversely proportional to the polymer molecular weight 
in an pseudo-steady state model for mifepristone release from PLGA films 21. An inversely 
linear relationship between diffusivity and polymer molecular weight was also used 19,22. In 
a piroxicam release model, an empirical correlation was proposed by determining drug 
diffusivity in monodisperse PLGA microspheres with different molecular weights 20. A 
similar approach was also used for determining a correlation between initial PLA molecular 
weight and apparent drug diffusivity 32. Exponential dependency of the diffusivity on the 
concentration of non-degraded PLA was also seem 30. The aforementioned models, 
however, have not considered the contribution in the enhanced drug diffusion through 
erosion and increasing porosity.
A mechanistic model should take into account the coupled aspects of PLGA degradation, 
erosion, and drug release while maintaining the mathematical form as simple as possible. In 
this work, a PLGA degradation-erosion model is proposed based on the method of moments, 
from which an analytical solution for the PLGA mass loss (erosion) rate is derived. The 
degradation-erosion model predicts the molecular weight change and mass loss reported in 
different experiments. Drug transport in the PLGA coating is modeled by utilizing a varying 
effective diffusivity that incorporates the effects of PLGA molecular weight change, 
porosity change, and drug partitioning in the solid and liquid-filled pores to describe 
simultaneous transport through the polymer solid and the pore space. The coupled 
degradation-erosion model and the drug release model is solved and validated for in vitro 
sirolimus release data using model parameter values reported in the literature. The release 
model is also formulated as a parameter estimation problem and solved via optimization to 
obtain the parameters with the best fit. Parameter exploration in the model is also performed 
to investigate the impact on changing the release profiles.
2. Theory and Methods
Drug release from a PLGA stent coating is a joint outcome of drug diffusion and the coating 
degradation and erosion. Both biphasic and triphasic release profiles are observed, with the 
latter having an additional phase of initial burse release. Burst release is typically found in 
large devices, which has been attributed to non-encapsulated drug or drug on the surface. 
Zhu and Braatz Page 3
J Biomed Mater Res A. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The burst effect is conveniently removed through adjusting the fabrication technique and is 
not considered in this model 31.
Our mathematical model focuses on the two releasing stages that are characteristic to PLGA 
drug release systems, involving an initial slow release and an enhanced release (Figure 1). 
The slow release (Stage 1 in Figure 1) is contributed by drug diffusion through the PLGA 
polymer solid phase at early times. For macromolecular drug, the diffusion release can be 
negligible due to small drug diffusivity. As polymer degradation continues and erosion start 
to occur with smaller products diffusing out of the matrix, pores are formed and opened up 
within the coating. Drug diffusion is accelerated by partitioning into and passing through the 
liquid-filled pores. Meanwhile, the molecular weight of PLGA polymers also decreases as a 
result of the degradation. Less molecular entanglement is present in the shorter PLGA 
chains, and drug diffusion through the PLGA polymer phase is also enhanced. Combining 
the drug diffusion enhancement from both pores and reduced PLGA chain length, a faster 
release (State 2 in Figure 1) is observed.
Heterogeneous degradation and erosion could occur in Stage 2 when the diffusion distance 
is relatively large and diffusion for small degradation products is slower than the generation 
rates. The accumulation of the acidic degradation products (in particular monomers) can 
increase towards the interior of the PLGA device, to further catalyze degradation. This 
phenomenon, known as the size-dependent autocatalytic effect, leads to spatial non-
uniformity and increases the complexity of drug release modeling. In the context of a stent 
coating, the coating thickness is on the order of 10 microns, which is small enough that the 
autocatalytic effect does not need to be considered 10.
Two key components in modeling drug release from PLGA stent coating include: (1) 
capture of the PLGA matrix change, that is, PLGA molecular weight change due to polymer 
degradation and porosity change as a result of erosion; and (2) description of the effective 
drug diffusivity varying with the matrix evolution. Increasing porosity and decreasing 
molecular weight change the drug diffusion rate, and collectively contribute to simultaneous 
drug diffusion through the solid and porous phases. These aspects are modeled in the next 
two subsections, respectively.
2.1 PLGA Degradation and Erosion Model
The degradation reaction of PLGA polymer Pn of length n (number of monomer units) is 
described by
(5)
where k is the reaction rate constant. The reaction assumes that the breakage of chemical 
bonds is random. Each polymer Pn can be generated via degradation of longer chains and 
consumed by breaking down into smaller chains.
In a PLGA stent coating, the change of polymer of length i is described by the diffusion-
reaction equation (6),
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(6)
where Pi is the concentration of polymer of length i, Di is the effective diffusivity, and x is 
the coating thickness. The diffusivity of each polymer, Di, is distinguished for different i, 
and is dependent on the average PLGA molecular weight Mw and matrix porosity φ. The 
reaction term describes all possible generation/consumption of polymer chains. In general 
the rate constant k can vary with position. For example, in the autocatalytic scenario, rate 
constant k(x) is an explicit function of local proton concentration. Equation (6) is the general 
model form for describing the PLGA degradation and erosion process.
Modeling the stent coating using the full complexity of model equation (6) for all polymer 
lengths is unrealistic, due to the complicated imperfectly known dependencies of diffusivity 
and rate constants on other factors, and computationally expensive, as a result of the huge 
number of partial differential equations. Existing models all utilize simplifications by 
adopting various assumptions. The two main assumptions of our model are:
1. The diffusion of monomers (or neutralizing ions from the release buffer, if any) is 
fast at the length scale of the stent coating and therefore the pH gradient within the 
coating is negligible. As a result, the degradation reaction occurs homogeneously 
throughout the coating. This assumption eliminates the spatial dependency of rate 
constant k.
2. Because of their smaller size, the monomers diffuse through the coating much 
faster than the oligomers, and contributes to majority of the mass loss (erosion) in 
early times. Based on this fact, the second assumption considers that all monomers, 
and only monomers, contribute to mass loss at early times before disintegration of 
the coating matrix occurs.
Under the second assumption, the diffusion terms in equation (6) for all polymer lengths can 
be separated from the degradation reaction. Leaving only the reaction terms in the equation, 
the model reduces to a set of ordinary differential equations that can be conveniently 
transformed utilizing the method of moments (see Appendix A for detailed description). 
With μn defined as the nth moment, the moments model is
(7)
(8)
(9)
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where μ0 stands for the total concentration (number) of polymer chains, μ1 is the total mass 
(or total number of polymeric units) without consideration of mass loss, and P1 is the 
concentration of monomers. Observe that μ1 is a constant in equation (8).
The moment model can be analytically solved to obtain (see Appendix A for the derivation),
(10)
(11)
where Xn,0 is the initial number-average degree of polymerization. From Assumption 2 and 
the assumption that the weight change induced by the addition of water molecules is 
negligible compared to the weight of polymer, the fraction of mass loss, or erosion rate, is 
calculated by
(12)
By definition, the number-average degree of polymerization is given as the total number of 
monomer units divided by the total number of chains,
(13)
As time t approaches infinity, equation (13) indicates that the number-average degree of 
polymerization approaches one, which corresponds to complete degradation into monomers. 
Equation (13) is easily converted to the number-average molecular weight by multiplying 
with the monomer molecular weight (for example, 83 for PLGA 50/50). Considering the 
loss of monomers, the modified number-average degree of polymerization is
(14)
The weight-average degree of polymerization (or molecular weight) is, however, not solved 
by the moments model because of the closure problem encountered on the second moment 
(illustrated in Appendix A). Alternatively, the commonly used first-order degradation model 
is adopted for modeling the weight-average molecular weight (MW) change,
(15)
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where Mw,0 is the initial weight-average MW.
2.2 Drug Transport Model
The drug transport in the coating proceeds by diffusion mechanism. Assuming that the drug 
is uniformly dispersed in the coating, the drug release is described by
(16)
where De is the effective drug diffusivity that is dependent on the evolving molecular weight 
and porosity.
As a consequence of the degradation and erosion, the key in predicting the drug release is 
finding a good description of the evolving effective diffusivity. As mentioned in the 
introduction, existing models typically consider only part of the affecting factors empirically 
(e.g., influence of molecular weight change, Table 1). In this model, an effective drug 
diffusivity is derived that incorporates the diffusivity in the polymer phase (Ds), the 
diffusivity in the liquid-filled pores (Dl), porosity (φ), and drug partitioning between the 
liquid-filled pores and solid PLGA phase (κ):
(17)
where the derivation is in Appendix B. The diffusivity in the polymer phase (Ds) further 
depends on the changing molecular weight. The various models summarized in Table 1 all 
correspond to this particular aspect. According to reptation theory in polymer physics, this 
diffusivity correlates with the average molecular weight (e.g., weight-average MW) through 
the scaling law 33,
(18)
with a theoretical value of power α equal to 2.
A comparison of the power law model (18) with the literature fit in model (3) is illustrated in 
Figure 2 for initial diffusivities measured in piroxiam-releasing monodisperse PLGA 
microspheres. The power law model (18) matches the experimental data with α = 1.714 and 
R2 = 0.9999. Extending the models to the low molecular weight region, the predicted 
diffusivity is much more reasonable for the power law model (18) and stays within the 
physical range. Based on the analysis, the power law model (18) is adopted for modeling Ds.
Equation (17) can be verified with two simple scenarios. When no pores exist, or φ = 0, the 
expression reduces to Ds, which is the drug diffusivity in the polymer solid. At the other 
extreme with the porosity of one, or φ = 1, the expression reduces to the aqueous drug 
diffusivity Dl.
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A quick note is that in equation (17), the effect of geometric factors was not included. Such 
factors include the tortuosity, which describes how tortuous the pore connections are, and 
constrictivity, which is a hindering effect if the pore size is comparable to the drug molecule 
size 34,35. Parameters for such factors are typically empirical, and could be incorporated 
with existing formulas 36. In this work, the factors of tortuosity and constrictivity are 
assumed constant. According to the knowledge of the authors, this is the first time in the 
literature that such an effective diffusivity formula is developed to describe simultaneous 
drug transport through degrading polymers and eroding pores in a stent coating, while taking 
into account the key controlling factors.
3. Results
In this section, the degradation and erosion model as well as the drug release model are 
validated by comparing with experimental data reported in the literature. Three 
distinguished experiments independently done in different groups are utilized for model 
validation. The information of the three sets of experiments are labeled and summarized in 
Table 2. For the three studies in Table 2, dataset 1 is for a PLGA microsphere (20 μm 
radius), dataset 2 is for a PLGA coating layer (loaded with sirolimus) on top of a ultra-high 
molecular weight poly(L-lactide) (PLLA) layer with no drug (therefore effectively a PLGA 
coating), and dataset 3 is a regular PLGA stent coating. Based on the two assumptions 
proposed for PLGA coating (or matrices) at small length scales that the proton gradient 
within the PLGA matrix is negligible and monomers contribute solely to the mass loss, the 
degradation and erosion occur homogeneously. Under such circumstances, the particular 
geometry of the PLGA matrix shall have little impact on the degradation and erosion rates 
and utilization of the three experimental studies are reasonable.
3.1 Predicting PLGA Erosion
The erosion model as derived in equation (12) describes the mass loss as a function of time 
and initial number-average MW. The model parameter, degradation rate constant k, is 
determined from the half-time of the number-average molecular weight decay. A reported 
value in the literature is used, with k = 2.5 × 10−7s−1 half-time is 35 days) 23. The measured 
mass loss in all the three datasets falls on the model prediction (Figure 3).
It is interesting to note that, even though the initial PLGA number-average MW is different 
in all three data sets, their model predictions overlap. The explanation lies in the 
insignificance of the term 1/Xn,0 compared with 1 in equation (12), due to the typical large 
initial number-average MW in PLGA polymers. Consequently, equation (12) is further 
simplified as
(19)
To the knowledge of the authors, it is the first time in the literature that an analytical model 
is proposed for describing mass loss in PLGA polymer thin films.
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3.2 Predicting PLGA Degradation
In theory either the number-average MW or weight-average MW can be used for 
characterizing the degradation. Compared with weight-average MW, the number-average 
MW is significantly affected by the presence of low MW polymers such as monomers and 
oligomers. The low MW polymers are, however, difficult to be detected due to the 
resolution limitation of equipments. As a result, the number-average MW measurements in 
PLGA degradation only represents contributions from polymers with size larger than the 
lower detection limit 23. The limit for PLGA is suggested to be oligomers with 9 polymeric 
units. As a result, the comparison of the model for number-average MW (equations 13 & 14) 
with experiments becomes difficult. As expected, model equations would predict much 
faster decay in number-average MW than what would be observed in experimental 
measurements.
Experimental determination of the weight-average MW is more robust as it is less 
influenced by the exclusion of small degradation products in the measurement. In the 
weight-average MW model, as described in equation (15), the model parameter kw is 
distinguished with parameter k used in the erosion model and the number-average MW 
change. While k corresponds to the reaction rate constant and is estimated via the half-time 
for the decay of the number-average MW, kw is conveniently obtained through the half-time 
for weight-average MW decay. The kw is acquired as kw = 7.5 × 10−7s−1 through the same 
experimental source for k 23. Similar values are reported in other experimental studies 20,22.
The degradation model predicting the weight-average MW is compared with the 
experimental datasets in Figure 4. Figure 4(a) plots the experimental measurements for two 
data sets. The model predictions are nearly perfect for data set 1, from which the model 
parameter kw was determined. The model predictions for data set 2 are satisfactory except 
for Day 20, where the particular data point is much lower than the model prediction. While 
the abrupt drop is proposed to be associated with the increase in mass loss at the same time 
point 9, the occurrence is unclear as no measurement was available for later times. The 
normalized molecular weight change is plotted for all three datasets in Figure 4(b). For data 
set 3, although the initial molecular weight is unknown, the model predicts the molecular 
weight change fairly well for the entire time course up to 60 days.
3.3 Simulations Match Sirolimus Release Data from PLGA Coating
To model the drug release, the effective drug diffusivity (17) requires information input for 
average MW and porosity. The average MW can be directly obtained via incorporating the 
validated first-order degradation model in the previous section. By assuming constant 
volume of the coating matrix and the same density for PLGA polymers of different lengths, 
the porosity is related to the mass loss (19) via
(20)
where φ0 is the initial porosity in the PLGA coating.
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The complete set of equations for describing the drug release is summarized in Table 3 for 
clarity. As a demonstration, the model is solved for simulating in vitro sirolimus release 
from PLGA stent coating to compare with experimental study 9. In the experiment, the 
PLGA coating loaded with sirolimus was coated on top of an ultra-high molecular weight 
PLLA layer that contained no drug. Compared with the PLGA coating layer, the PLLA 
undergoes much slower degradation and erosion because of its high MW and the chemical 
composition. As a result, even though the polymer matrix is fully biodegradable, the PLGA 
layer acts as if it is a coating layer on the PLLA layer. In the simulation, the wash out 
boundary condition is utilized on the external surface of the stent coating. While the initial 
porosity is a parameter dependent on the manufacturing procedures of the PLGA coating, an 
initial porosity of zero is used in the simulation as the micrographs of the PLGA coating 
morphology in the experiments indicated absence of micro-cavities in the beginning 9. 
Because both sirolimus and piroxiam are hydrophobic drugs with small molecule size, the 
power law model (18) for Ds and α = 1.714 are adopted for modeling sirolimus from Section 
2.1.
The model is solved using the numerical method of lines. The spatial dimension (x) is 
discretized, which results in a system of ordinary differential equations (ODE). The system 
of ODEs is conveniently solved using a standard ODE solver in Matlab (ode15s). The 
numerical procedure is straightforward and details are not included here 37.
Sirolimus release of two loadings (1% and 2% loadings, both from dataset 2 in Table 2) was 
compared for the experimental measurements and model simulations (Figure 5). The 
simulated sirolimus release in the model matches the experimental data quite closely. 
Because the loadings are relatively low, the drug could be considered as in a dissolved state. 
As a result, the percentage release profiles overlap for the two loadings both experimentally 
and in the model. Only three parameters are used in the drug release model: the drug 
diffusivity in the initial PLGA solid (Ds0), aqueous drug diffusivity (Dl0), and drug 
partitioning coefficient (κ). The values of the parameters are directly obtained from ranges 
reported in the literature (summarized in Table 4). The model predictions capture the 
biphasic release behavior, and describe the process of simultaneous diffusion through 
polymer solids and the liquid-filled pores.
4. Discussion
4.1 Model Parameters
In order to obtain the parameters that best fit the experimental data, the model is also 
formulated as a parameter estimation problem. The parameter estimation defines an 
objective function that minimizes the summed square error (SSE) between values of model 
predictions and experimental data,
(20)
and is conveniently solved using the optimization toolbox (fmincon) in Matlab. The 
parameter values obtained via optimization are very close to the initial values used in the 
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model (Table 4). The small difference indicates that the parameter values are optimal and 
further supports the validity of the model.
The drug release model in this work is also compared with existing models (Figure 6). Using 
a constant diffusivity in the polymer coating results in a very limited release. Including the 
MW dependency in the diffusivity results in significant enhancement in the drug release. 
However, the discrepancy between that model and our model indicates that the contribution 
from diffusion through the pores described in our model is significant. As the comparison 
suggests, the simultaneous diffusion through the polymer solid and the pore space is the 
most appropriate mechanism for describing sirolimus release in PLGA stent coating, and is 
only captured in our proposed model.
4.2 Analysis of the Hydrophobicity Parameter on Release Rate
The partitioning coefficient (κ) reflects the hydrophobicity of the drug. The smaller the 
partition coefficient, the less water-soluble the drug is and the higher the tendency that the 
drug prefers to stay within the polymer solid. For sirolimus, the partitioning coefficient is 
very low because of its high hydrophobicity 38,39. The effect of the partitioning coefficient is 
illustrated in Figure 7 by fixing the other parameters (e.g., drug diffusivities in the polymer 
solids and aqueous phase). With higher partitioning coefficient value, faster release is 
predicted. The release profiles all exhibit biphasic characteristics. For all release profiles, the 
release profiles have a lower bound by the curve corresponding to κ = 0.
4.3 Limitations and Possible Extensions of the Model
The model developed in this work considers the various important factors that collectively 
regulate the drug release in PLGA stent coatings. While demonstrating successful matching 
between model simulation and experimental studies, the model does have limitations and it 
is worthwhile for further research in several aspects that could produce even better 
predictability and extended applicability.
The first limitation lies in the simplifications adopted in the development of the effective 
drug diffusivity. As pores are formed randomly throughout the polymer matrix, the path 
through the pores could zigzag and the tortuosity effect may be significant. 
Correspondingly, the diffusivity contribution corresponding to the pores would be reduced. 
This modification would correct the higher predicted release than measured data at times 
around 10 to 20 days in Figure 5. Usually included as an empirical factor, the tortuosity 
effect could be potentially incorporated if sufficient information was available.
While this work focuses on hydrophobic drug with relatively small size, which are typically 
used in drug-eluting stent applications (i.e., sirolimus, with MW of less than 1 kDa), the 
model application could be extended to the release of macromolecular hydrophilic drugs 
(such as proteins or genes). In such situations, another factor besides the tortuosity effect, 
called constrictivity, would become important. The constrictivity describes the delay and 
hindrance in diffusion through pores when the pore size is comparable to the drug molecule 
size, and expressions for describing the factor are available. As a result, utilization of the 
constrictivity effect would require knowledge of the pore sizes in the coating.
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In the erosion model, only monomers were included as the source for weight loss so that 
simple analytical expression could be derived. In reality, dimers, trimers, and other 
oligomers may all contribute to the weight loss to varying extents. Even though treated with 
simplification in this work, the autocatalytic effect could have some influence in PLGA stent 
coating systems. Capture of those details in the degradation and erosion model may offer 
extra benefits in improving the drug release prediction.
A further limitation of the model developed here is the consideration of dissolved (well-
dispersed) drug state. While the mechanistic model is verified with release of sirolimus at 
relatively low loadings, much higher drug loadings in the stent coating (10% or even higher) 
are not uncommon in the application of drug-eluting stents 40. The latter could lead to both 
initial burst and aggregation of drug (for example, crystal formation), for which the current 
model will need to be extended to consider the drug dissolution mechanism 41.
5. Conclusions
This paper develops a complete model set for describing the PLGA degradation and erosion 
and coupled drug release from PLGA stent coating. An analytical and simple expression for 
the PLGA mass loss was derived for the first time in the literature, together with an 
analytical expression for the number-average degree of polymerization (or molecular 
weight) change. The mass loss model and the first-order degradation model are validated 
with experimental data from the literature.
Simultaneous drug diffusion through polymer solid with changing average molecular weight 
(MW) and liquid-filled pores was modeled, and an effective drug diffusivity model was 
derived taking into account various factors including polymer MW change, diffusivity in the 
polymer, diffusivity in the liquid-filled pores, and drug partitioning between solid and liquid 
phases. The model was demonstrated for sirolimus release from PLGA stent coating and 
matched well with the experimental data in the literature. Comparison of the proposed 
model with existing models revealed the significance of simultaneous sirolimus diffusion 
through polymer solid and pore space. The impact of drug hydrophobicity was also 
demonstrated using the model.
The mechanistic model developed here has potential for applications to the design of PLGA 
coatings for drug-eluting stents. The model can also be extended for applications to other 
PLGA-based drug delivery systems. The limitations are also discussed that provides 
guidance in possible model improvements.
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Appendix A. Derivation of the Differential Moment Equations
Under the assumptions in Section 2, the partial-differential equations are reduced to ordinary 
differential equations. The change of polymers of different length is given by,
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(A1)
(A2)
(A3)
(A4)
(A5)
(A6)
(A7)
Define the nth moment of the polymers as
(A8)
Physically, the zeroth moment corresponds to the total number of polymers in the system, 
while the first moment stands for conservation of polymer units.
Summing all equations (A1)–(A7) gives an equation for the zeroth moment,
(A9)
Similarly, the first moment is given by
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(A10)
which implies that μ1 is a constant.
The change of monomer is described by
(A11)
The second moment can be derived as
(A12)
However, it is clear that the equations for the higher order moments do not have closure 
(that is, the differential equations for the ith moment are algebraic functions of higher order 
moments).
With initial condition μ0(t = 0) = μ1/Xn,0, where Xn,0 is the initial number-average degree of 
polymerization, and P1(t = 0) = 0, equations (A9) and (A11) are analytically solved to give
(A13)
(A14)
Appendix B. Derivation of the Effective Diffusivity in the Coating
Consider one-dimensional transport in a small control volume consisting of polymer matrix 
and pore space (Figure B1). The drug transport is contributed by both diffusion through the 
pore space and diffusion through the polymer solid.
The drug transport through the polymer solid is given by
(B1)
and the drug transport through the pore space is given by
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(B2)
where A′ is the interface area between the solid and pore space within the micro control 
volume, JSL is the flux through the solid and liquid interface, and CS and CL denotes the 
concentration within the polymer solid and the liquid filled pores, respectively.
Summing equations (B1) and (B2) gives an expression for the total drug diffusion,
(B3)
Note that the interfacial diffusion terms cancel due to the opposite signs. Assuming that the 
drug is in partitioning equilibrium between the pore phase and solid polymer phase gives
(B4)
where κ is the partition coefficient.
Substituting equation (B4) into (B3) gives
(B5)
The average drug concentration over the entire control volume is given by
(B6)
As φ is only a function of time (uniform degradation throughout the coating),
(B7)
Substituting (B6) and (B7) into (B5) gives
(B8)
For infinitesimal Δx,
(B9)
Correspondingly, the average concentration in the coating is described by
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(B10)
where De is the effective diffusivity defined as
(B11)
Figure B1. 
Illustration of one-dimensional drug diffusion through pores and polymer solid in a small 
control volume.
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Figure 1. 
Two-stage scheme of the drug release coupled to PLGA degradation and erosion. Stage 1: 
slow release by diffusion through the matrix; Stage 2: enhanced released contributed by 
diffusion through both matrix and micro-porous structured formed by polymer matrix 
degradation and erosion.
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Figure 2. 
Estimation of the dependency of drug diffusivity in the polymer phase on the PLGA average 
molecular weight. The power law model gives a more physically reasonable prediction at 
low molecular weights than model (3) in the literature.
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Figure 3. 
Weight loss predicted by the analytical erosion model matched the three experimental 
datasets.
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Figure 4. 
Molecular weight change predictions using the degradation model. (a) Model prediction for 
weight-average MW in data set 1 and data set 2. (b) Normalized weight-average MW in all 
three data sets compared with model prediction.
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Figure 5. 
Model simulation matches experimental data of sirolimus release from PLGA coating.
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Figure 6. 
Sirolimus release profiles predicted in different models.
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Figure 7. 
Impact of drug hydrophobicity on the drug release behaviors in PLGA stent coating.
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Table 1
Diffusivity dependency on molecular weight in literature models
Model Expression Reference
D(M ) = D0
M0
M
(1) Charlier et al. 21
D(M
w
) = D0 +
k
M
w
(2) Siepmann and Peppas 19
ln D = − 0.347x 3 + 01.394x 2 − 104.950x + 316.950
x = ln M
w
(3) Raman et al. 20
D(M
n
) = D0 − k ln Mw (4) Wada et al.32
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Table 2
Sources and information of the experimental data used for model validation
Label PLGA Composition(LA:GA)
PLGA weight-average
MW Reference
Dataset 1 50:50 37954 Batycky et al. 23
Dataset 2 53:47 7.69 × 104 Wang et al. 9
Dataset 3 Unreported Unreported Xi et al. 10
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Table 3
Summary of complete set of equations for the drug release model
Drug Transport ∂C∂ t =
∂
∂ x (De(Mw, φ) ∂C∂ x ) (16)
Effective diffusivity D
e
=
(1 − φ)D
s
+ κφDl
1 − φ + κφ (17)
Diffusivity in polymer solid D
s
= D
s0( MwM
w,0 )−α (18)
PLGA average MW M
w
= M
w,0e
−k
w
t (15)
Porosity change φ = φ0 + (1 − φ0)(1 + e
−2kt
− 2e −kt) (20)
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Table 4
Model parameters and estimated values via optimization
Model Parameters Initial Values Estimation via Optimization Reference Range
Partition coefficient κ 10−4 1.0035 × 10−4 10−6 ∼ 10−3 38,39
Initial diffusivity in PLGA polymer Ds0(μm2 / s) 10−5 9.9826 × 10−6 10−6 ∼ 10−4 20,22
Diffusivity in aqueous phase Dl0(μm2 / s) 50 49.6386 10 ∼ 103 33
MW change model parameter a 1.714 1.7179 ∼2 33
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